ValiSeek CEO Dr Suzy Dilly tells Proactive their VAL401 treatment was found to have a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment.
The company had previously reported back in September that 2mg doses of VAL401 were “broadly safe and tolerated”, while the treatment also demonstrated “suitability of our proposed treatment paradigm”.
ValiSeek is a Joint Venture company between () and Tangent Reprofiling Limited.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
